Arrowhead Pharmaceuticals Closes Underwritten Offering with Gross Proceeds of $450.0 Million

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that on January 5, 2024, it closed the previously announced underwritten registered offering of 15,790,000 shares of its common stock, par value $0.001 per share (“Common Stock”). The offering was priced at $28.50…

Read MoreArrowhead Pharmaceuticals Closes Underwritten Offering with Gross Proceeds of $450.0 Million

U.S. Food and Drug Administration Approves ZELSUVMI™ as a First-in-Class Medication for the Treatment of Molluscum Contagiosum

ZELSUVMI™ is expected to be commercially available during the second half of 2024 Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that the U.S. Food and Drug Administration (FDA) has approved ZELSUVMI™ (berdazimer topical gel, 10.3%) for the treatment of molluscum contagiosum…

Read MoreU.S. Food and Drug Administration Approves ZELSUVMI™ as a First-in-Class Medication for the Treatment of Molluscum Contagiosum

Optum Rx community and independent initiatives support patients and pharmacists

These initiatives included partnerships with pharmacists, reimbursing them for connecting their patients to services that address basic needs such as food, nutrition, transportation, housing, and baby supplies. In particular, Optum Rx focused on critical areas, including community resources, for underserved…

Read MoreOptum Rx community and independent initiatives support patients and pharmacists

Delaware Court Rules in Favor of AIM ImmunoTech and Upholds Board’s Determination that Activist Group’s Nominations Are Invalid

AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the Delaware Court of Chancery (the “Court”) ruled that the nomination notice (the “Notice”) submitted by a member of a group of individuals who are seeking to nominate…

Read MoreDelaware Court Rules in Favor of AIM ImmunoTech and Upholds Board’s Determination that Activist Group’s Nominations Are Invalid

Viral Vectors & Plasmid DNA Manufacturing Market Report 2024-2034 – Shaping the Future of Rare Disease Treatment with Viral Vector Solutions

The “Viral Vectors & Plasmid DNA Manufacturing Market Report 2024-2034” report has been added to ResearchAndMarkets.com’s offering. Overall world revenue for the viral vectors and plasmid DNA manufacturing market is forecast to surpass US$1.35 billion in 2024, with strong revenue growth through to 2034.…

Read MoreViral Vectors & Plasmid DNA Manufacturing Market Report 2024-2034 – Shaping the Future of Rare Disease Treatment with Viral Vector Solutions
Sensei

Organigram Announces Mailing of Management Information Circular in Connection with Annual General and Special Meeting

Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), a leading licensed producer of cannabis, announced today that it has mailed and filed a management information circular (the “Circular”) and related materials (the “Meeting Materials”) for its annual…

Read MoreOrganigram Announces Mailing of Management Information Circular in Connection with Annual General and Special Meeting

Healthcare Just Got Better in Glendale: MY DR NOW Opens New Clinic with More Access and Flexibility!

Glendale! MY DR NOW, the revolutionary healthcare provider that vows to make healthcare ridiculously easy, is bringing a brand-new clinic to our neighborhood to modernize how healthcare is being delivered. It’s not just any clinic; it’s a part of their…

Read MoreHealthcare Just Got Better in Glendale: MY DR NOW Opens New Clinic with More Access and Flexibility!